An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

854

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Crohn Disease

Interventions

DRUG: Ozanimod

Sponsor

Celgene